TG Therapeutics Inc (TGTX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $30.90
• Market Cap: $4.71B
• P/E Ratio: 10.71
• EPS: $2.77
• 52-Week High: $46.48
• 52-Week Low: $25.28

Market Sentiment

TG Therapeutics Inc currently has a Bullish sentiment score of 0.29.

About TG Therapeutics Inc

TG Therapeutics, Inc. (TGTX) is a distinguished biopharmaceutical company headquartered in New York, focused on developing and commercializing novel therapies for B-cell malignancies and autoimmune diseases. The company boasts a diverse pipeline of innovative product candidates, utilizing cutting-edge drug development technologies that solidify its stance as a front-runner in oncology and autoimmune treatment sectors. Driven by a mission to fulfill unmet medical needs, TG Therapeutics is comm...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for TG Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does TGTX pay dividends?

TG Therapeutics Inc (TGTX) does not currently pay a regular dividend.

What is TGTX's P/E ratio?

TG Therapeutics Inc has a price-to-earnings (P/E) ratio of 10.71.

What is TGTX's market cap?

TG Therapeutics Inc (TGTX) has a market capitalization of $4.71B with a current stock price of $30.90.